Almatica Pharma LLC announced today that the U.S. FDA has approved a supplemental New Drug Application for duloxetine hydrochloride, oral, setting a final market exit date for the product in 2026. The approval is expected to position the company to capitalize on downstream profitability as the branded market for Cymbalta reaches the end of patent exclusivity.